Physician profile
Igal Mirman
NPI 1598298317
$18,403.49
in general payments reported to CMS, 2019-2025
38 companies · $2,195 in 2025
The $2,195 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $125 · 2021: $164 · 2023: $585 · 2024: $15K · 2025: $2,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,130 · Food and Beverage: $6,393 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,275 · Travel and Lodging: $1,085 · Education: $96.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,130.00 |
| Food and Beverage | $6,393.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,275.00 |
| Travel and Lodging | $1,084.63 |
| Education | $96.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $10,253.98 | 2023-2025 | Rystiggo, Zilbrysq, Briviact |
| Alexion Pharmaceuticals, INC. | $3,648.83 | 2020-2025 | Ultomiris |
| Csl Behring | $998.46 | 2023-2025 | Hizentra |
| Argenx US, INC. | $509.75 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals LP | $445.86 | 2023-2025 | Wainua |
| Takeda Pharmaceuticals U.S.A., INC. | $359.94 | 2024-2025 | Hyqvia |
| Janssen Scientific Affairs, LLC | $283.45 | 2024-2025 | |
| Genentech USA, INC. | $155.63 | 2019-2024 | Evrysdi |
| Biogen, INC. | $130.08 | 2024-2025 | Spinraza, Skyclarys, Tysabri |
| Alnylam Pharmaceuticals INC. | $115.26 | 2023-2025 | Amvuttra |
| Merz Pharmaceuticals, LLC | $110.91 | 2025 | Xeomin |
| Mallinckrodt Hospital Products INC. | $100.44 | 2024-2025 | Acthar |
| Emd Serono, INC. | $97.50 | 2024 | |
| Neurelis, INC. | $85.97 | 2024-2025 | Valtoco |
| Genentech, INC. | $84.33 | 2024 | Evrysdi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82.81 | 2025 | |
| Neurocrine Biosciences, INC. | $73.73 | 2024-2025 | Ingrezza |
| Catalyst Pharmaceuticals, INC. | $67.03 | 2024-2025 | |
| Tanabe Pharma America, INC. | $65.44 | 2024-2025 | Radicava |
| Amgen INC. | $64.61 | 2024-2025 | Uplizna |
| Genzyme Corporation | $62.30 | 2025 | |
| Allergan, INC. | $62.10 | 2021 | |
| Jazz Pharmaceuticals INC. | $61.25 | 2024 | |
| Novartis Pharmaceuticals Corporation | $60.78 | 2024-2025 | |
| Pfizer INC. | $54.71 | 2024-2025 | |
| Hospira, INC. | $40.09 | 2024 | |
| Lundbeck LLC | $38.90 | 2024-2025 | Vyepti |
| Grifols USA, LLC | $37.39 | 2025 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $37.10 | 2024-2025 | Horizant |
| Sk Life Science, INC. | $33.08 | 2024 | |
| Tg Therapeutics, INC. | $30.96 | 2025 | |
| Cycle Pharmaceuticals INC | $29.24 | 2025 | Tascenso Odt, Bafiertam |
| Ipsen Biopharmaceuticals, INC | $23.98 | 2025 | Dysport |
| Octapharma USA, INC. | $23.65 | 2024 | Octagam Immune Globulin (Human) |
| Otsuka America Pharmaceutical, INC. | $21.99 | 2024 | Rexulti |
| Averitas Pharma INC. | $18.78 | 2025 | Qutenza |
| Scilex Pharmaceuticals INC. | $18.29 | 2024 | |
| Lilly USA, LLC | $14.89 | 2024 | Emgality, Reyvow |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igal Mirman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.